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Article

Evidence for differential viral oncolytic efficacy in an
in vitro model of epithelial ovarian cancer metastasis
Jessica G Tong1,2, Yudith Ramos Valdes1, John W Barrett3, John C Bell4,5, David Stojdl6, Grant McFadden7, J Andrea McCart8,
Gabriel E DiMattia1,9,10,11 and Trevor G Shepherd1,2,10,11

Epithelial ovarian cancer is unique among most carcinomas in that metastasis occurs by direct dissemination of malignant cells
traversing throughout the intraperitoneal fluid. Accordingly, we test new therapeutic strategies using an in vitro three-dimensional
spheroid suspension culture model that mimics key steps of this metastatic process. In the present study, we sought to uncover
the differential oncolytic efficacy among three different viruses—Myxoma virus, double-deleted vaccinia virus, and Maraba
virus—using three ovarian cancer cell lines in our metastasis model system. Herein, we demonstrate that Maraba virus effectively
infects, replicates, and kills epithelial ovarian cancer (EOC) cells in proliferating adherent cells and with slightly slower kinetics in
tumor spheroids. Myxoma virus and vaccinia viruses infect and kill adherent cells to a much lesser extent than Maraba virus, and
their oncolytic potential is almost completely attenuated in spheroids. Myxoma virus and vaccinia are able to infect and spread
throughout spheroids, but are blocked in the final stages of the lytic cycle, and oncolytic-mediated cell killing is reactivated upon
spheroid reattachment. Alternatively, Maraba virus has a remarkably reduced ability to initially enter spheroid cells, yet rapidly
infects and spreads throughout spheroids generating significant cell killing effects. We show that low-density lipoprotein receptor expression in ovarian cancer spheroids is reduced and this controls efficient Maraba virus binding and entry into infected cells.
Taken together, these results are the first to implicate the potential impact of differential viral oncolytic properties at key steps of
ovarian cancer metastasis.
Molecular Therapy — Oncolytics (2015) 2, 15013; doi:10.1038/mto.2015.13; published online 23 September 2015

INTRODUCTION
Epithelial ovarian cancer (EOC) is the most lethal gynecologic malignancy and represents the sixth most commonly diagnosed cancer
among women in the developed world.1 A lack of effective therapeutic options, coupled with the highly heterogeneous nature of
EOC, and being typically diagnosed at an advanced metastatic
stage, contribute to the lethality of EOC.2,3 Current therapeutic
strategies involve exhaustive cytoreductive surgery and postoperative platinum- and taxane-based chemotherapy.4–6 However,
effective treatment is complicated by the manifestation of EOC as
multiple histotypes, which are differentially responsive to platinum- and taxane-based combination chemotherapy treatments.7
Furthermore, patients that initially respond well to platinum therapy
almost inevitably relapse with chemo-resistant disease resulting in
reduced overall survival. Thus, there is a critical need for targeted
and durable therapeutic alternatives beyond the standard first-line
chemotherapeutic agents.8–10
Oncolytic virotherapy promotes selective viral infection and lysing
of cancer cells. The specific nature of oncolytic virus therapy stems
from the selection of non- or low-pathogenic nonhuman viruses that

display tropism for cancer-associated genetic mutations or aberrant
signaling.11 Myxoma virus (MYXV) is a European rabbit-specific poxvirus that has not been shown to cause disease in humans and is used as
a pesticide to control Australian rabbit populations.12 MYXV displays
tropism for cancer cells with upregulation in active AKT signaling and
dysfunctional p53, which is found in essentially all high-grade EOC.13
Conversely, vvDD is an engineered poxvirus with deleted vaccinia
growth factor and viral thymidine kinase genes, which limit its infection to cells harboring upregulated EGFR/RAS signaling commonly
observed in low-grade EOCs.14 Point mutations in the strain of MRBV
used in this study modify the matrix protein (M) and glycoprotein (G)
effectively boosting its replicative capacity in cancer cells while rendering it unable to counteract an antiviral type I interferon response
in healthy cells. Though its specific tropism for cancer cells is relatively
undefined, MRBV has been shown to have potent oncolytic effects in
a broad range of cancer cells, including EOC.15
The mode of EOC metastasis is unique among most solid
malignancies, and therefore it likely possesses distinct and novel
mechanisms. EOC metastasis occurs via the shedding of malignant cells from the primary tumor into the peritoneal cavity; this
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Figure 1 In vitro three-dimensional spheroid model system of ovarian cancer metastasis. (a) Ovarian cancer cells are grown as adherent proliferating
monolayer cultures, and are transferred to Ultra-Low Attachment tissue culture plastic-ware where they naturally form multicellular aggregates,
or spheroids, when in suspension culture. Spheroids are subsequently transferred back to standard tissue culture plastic to facilitate adhesion and
growth of cells out of viable spheroids. (b) Phase contrast images of ovarian cancer cells in each of the culture conditions outlined in panel a. (c) Left:
Phase contrast microscopic image of freshly-collected ovarian cancer patient ascites indicating the presence of spheroids in suspension. Right: Image
representing ovarian tumor nodules implanted on the peritoneal wall of an ovarian cancer patient at the time of laparoscopic surgery.

can occur in the context of ascites, an exudative fluid commonly
associated with advanced-stage disease. Single cells in suspension
within the ascites are susceptible to death through anoikis; thus
aggregation of single cells into multicellular spheroids facilitates
escape from cell death.16,17 Furthermore, EOC spheroid survival
is maintained in the low-nutrient environment of the ascites by
undergoing cellular quiescence and autophagy.18,19 This tumor cell
dormancy phenotype within spheroids is thought to allow persistence of microscopic EOC secondary deposits after treatment with
first-line chemotherapeutics and support growth under more favorable conditions.20 In addition, spheroids have an enhanced capacity
to attach and invade mesothelial-lined surfaces in the peritoneal
space promoting the formation of secondary tumor nodules.16
We postulate that in the context of metastatic ovarian cancer, the
ability to kill dormant tumor cells is essential to eradicate the potential for disease recurrence. In this study, we compare three oncolytic
viruses, MYXV, vvDD and MRBV, in an in vitro spheroid culture model
of ovarian cancer metastasis to determine whether they have the
potential to kill dormant tumor cells residing in spheroids.
RESULTS
Oncolytic effects of MYXV, vvDD, and MRBV in ovarian cancer cell
lines
To begin to define the optimal oncolytic viral approach to the eradication of dormant EOC cells in spheroids, we applied three different viruses in an in vitro three-dimensional spheroid culture system,
which we have established to model metastatic EOC (Figure 1).
Distinct molecular characteristics typify the lifecycle of metastatic
Molecular Therapy — Oncolytics (2015) 15013

ovarian cancer cells as they move from a proliferative state in the
solid tumor to the resting state in ascites-suspended spheroids and
finally when these structures attach to a secondary site and cells
proliferate to form a metastatic lesion. Herein, we performed oncolytic infections using proliferating adherent EOC cell lines, spheroids
cultured in suspension, and spheroid reattachment to tissue culture
substratum to determine whether molecular and cellular changes
at these specific steps would affect oncolytic virus cell killing efficacy. We selected the established HEYA8, SKOV3 and OVCAR8
cell lines since they have been well-characterized genomically
(Supplementary Table S1) and have been predicted to represent different EOC subtypes based on this data.21
First, we performed parallel viral infections of adherent EOC cell
lines with established spheroids in suspension (Figure 2a). Even in
proliferating adherent cultures, we found that MYXV, vvDD, and
MRBV were capable of inducing oncolysis of EOC lines with differential killing capacities among the three viruses and across cell
lines (Figure 2). MYXV displayed the least potent killing and was
unable to induce significant oncolysis at less than a multiplicity of infection (MOI) 1 in all cell lines (Figure 2b). vvDD exhibited
oncolysis at similar concentrations as MYXV, but was able to induce
greater loss of viability in comparison. Among the three EOC cell
lines, OVCAR8 cells displayed greatest sensitivity to vvDD and MYXV
infection whereas SKOV3 cells were most resistant in adherent
culture infections. In a similar fashion, when tested using ovarian
cancer patient ascites-derived primary cultures, vvDD yielded better oncolytic activity than MYXV in the majority of clinical samples
(Supplementary Figure S1). Although both MYXV and vvDD were
Official journal of the American Society of Gene & Cell Therapy
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Figure 2 Analysis of MYXV, vvDD, and MRBV oncolytic-mediated killing of EOC cell lines in adherent and spheroid culture. (a) Schematic representation
of viral infection of ovarian cancer cells in adherent and spheroid culture. (b) HEYA8, SKOV3, and OVCAR8 cells were infected at increasing concentrations
to a maximum of multiplicity of infection (MOI) 10, as indicated; UV-inactivated virus was used at a MOI of 10. Cell viability was measured after 72 hours
using CellTiter-Glo. (c) HEYA8, SKOV3, and OVCAR8 cells were seeded to Ultra-Low Attachment dishes to form spheroids over 3 days, then infected at
the indicated doses; spheroid cell viability was assayed as in panel b (*P < 0.05). EOC, epithelial ovarian cancer; MYXV, Myxoma virus.

able to induce modest oncolysis of EOC cell lines in adherent c ulture,
infection-mediated cell killing was dramatically reduced in EOC
spheroids for all cell lines tested (Figure 2c). vvDD was completely
ineffective at inducing oncolysis of SKOV3 spheroids, but it did
maintain some oncolytic activity in HEYA8 and OVCAR8 spheroids.
These findings using MYXV and vvDD were in stark contrast to
results of MRBV infection, which induced robust oncolysis-mediated
cell killing across all EOC cell lines in adherent culture even at an MOI
of 0.001 (Figure 2b). In contrast, MRBV infection of heterogeneous
patient-derived cells yielded highly variable oncolytic effects with one
sample exhibiting robust MRBV-mediated loss in cell viability similar
to established EOC cell lines (Supplementary Figure S1). However, a
potent oncolytic effect was observed in MRBV-infected HEYA8 and
SKOV3 spheroids where dramatic loss of cellular viability was evident
with as little as MOI 0.01 at three days postinfection. Interestingly, we
observed a significant reduction in MRBV oncolytic effects in OVCAR8
spheroids compared with adherent cells s uggesting that EOC cells
may have the capacity to acquire resistance against MRBV infection
in three-dimensional spheroid form (Figure 2c).

Official journal of the American Society of Gene & Cell Therapy

MRBV is significantly faster at inducing oncolysis of EOC cells
We hypothesized that the potent oncolysis of EOC cells by MRBV
may be due to a rapid ability to replicate its small RNA-based
genome, allowing it to complete multiple rounds of infection within
the experimental time frame of 72 hours. MRBV contrasts the large
poxviruses, MYXV and vvDD, which have been shown to take up to
several days to complete their life cycle, thus they may only complete a single round of infection within 72 hours.
To assess this directly in our system, we sought to compare viral
infection kinetics among MYXV, vvDD, and MRBV in both adherent
and spheroid cultures. Cells were infected with an MOI 10 to maximize infection of all cells at the initial time point. We then assayed cell
viability as an initial surrogate to observe virus infection over 5 days. In
adherent culture, we found that MRBV was able to induce oncolysis in
both HEYA8 and OVCAR8 cells within 24 hours of infection (Figure 3a).
In support of our previous findings (Figure 2b), MRBV exhibited a
significant delay of infection in adherent SKOV3 cells taking over 48
hours to die from MRBV infection. In contrast, complete oncolysis of
adherent EOC cells by MYXV and vvDD required up to 5 days.

Molecular Therapy — Oncolytics (2015) 15013
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Figure 3 Rapid kinetics of MRBV-mediated killing of epithelial ovarian cancer (EOC) cells and spheroids compared with MYXV and vvDD. (a) MRBV-mediated
cell killing is observed within 24 hours in adherent EOC cells, but requires longer incubation in SKOV3 cells. Oncolysis of adherent cells by MYXV and vvDD
is considerably slower. (b) MRBV produces rapid cell killing in spheroids, but there is an incomplete oncolytic effect in SKOV3 and OVCAR8 spheroids. EOC
spheroids have reduced viability due to vvDD infection by 5 days, yet remain relatively resistant to MYXV infection (*P < 0.05). MYXV, Myxoma virus.
Table 1

Quantification of oncolytic virus production in

infected adherent ovarian cancer cells and spheroids
Adherent culturea
HEYA8

SKOV3

OVCAR8

MYXV

1.38 ± 0.08 × 105

5.37 ± 0.21 × 105

1.30 ± 0.13 × 105

vvDD

7.78 ± 1.22 × 106

2.78 ± 0.35 × 106

2.83 ± 0.59 × 106

MRBV

5.52 ± 1.55 × 107

4.82 ± 1.11 × 107

2.38 ± 0.43 × 107

Spheroid culture

OVCAR8 spheroids were relatively resistant to MRBV-mediated
cell killing with a limited extent of cell death similar to what
we observed for vvDD. This significantly contrasts MRBV infections of adherent EOC cell lines, including OVCAR8 cells, which
displayed significant cell death within 24 hours. These unexpected results reinforce the idea that the potential underlying
mechanisms governing oncolytic efficacy in EOC cells may be
quite dynamic, and stress the importance of preclinical testing in
complementary in vitro model systems.

b

HEYA8

SKOV3

OVCAR8

MYXV

8.54 ± 2.07 × 105

1.75 ± 0.33 × 105

1.12 ± 0.34 × 105

vvDD

1.60 ± 0.21 × 106

3.12 ± 1.58 × 105

6.04 ± 1.39 × 105

MRBV

1.09 ± 0.15 × 10

6.80 ± 0.78 × 10

1.58 ± 0.41 × 106

8

6

a
In adherent culture, 2.5 × 104 cells were infected in 24-well dishes at MOI
10 (2.5 × 105 pfu). bIn spheroid culture, 5 × 104 cells were infected in 24-well
Ultra-Low Attachment cluster plates at MOI 10 (5 × 105 pfu).
MOI, multiplicity of infection.

We have previously shown that MYXV replication is attenuated
in EOC spheroids compared to infection of adherent monolayer
cells.22 Therefore, we tested the kinetics of MYXV, vvDD, and
MRBV infection in spheroids to compare directly with our results
using proliferating adherent cell lines. We found that MYXV was
largely ineffective at inducing detectable oncolysis in EOC spheroids by three days, but cell viability was reduced in HEYA8 and
OVCAR8 spheroids by 5 days postinfection (Figure 3b). Although
a 72-hour infection of EOC spheroids with vvDD yielded little
oncolysis, extending the time course to 5 days was sufficient for
marked loss of HEYA8 and OVCAR8 spheroid cell viability. Time
course infections with MRBV resulted in cell death between 48
and 72 hours for both HEYA8 and SKOV3 spheroids. Interestingly,
Molecular Therapy — Oncolytics (2015) 15013

MRBV produces significantly more virus progeny than MYXV and
vvDD
We postulated that the observed differences in oncolytic effect
among the three viruses in our spheroid culture system were also
impacted by the efficiency of total virus production. To assess this
directly, we infected adherent cells and spheroids and titrated total
infectious virus particles. MRBV infection of adherent EOC cell lines
yielded significantly more infectious viral progeny compared to both
vvDD (7- to 17-fold increase) and MYXV (90- to 400-fold increase)
(Table 1). Moreover, the number of viral progeny produced from
MRBV infection in adherent culture was relatively similar among the
three EOC cell lines. In spheroids, however, infectious progeny produced by MRBV infection was more variable among cell lines. MRBV
infection of SKOV3 spheroids yielded 16-fold less virus and OVCAR8
spheroids yielded 69-fold less than HEYA8 spheroids (Table 1). These
MRBV titers were congruent with our results of cell viability demonstrating reduced MRBV oncolysis of OVCAR8 spheroids (Figure 2c).
The number of viral progeny produced from vvDD infections was
similarly reduced in spheroids among cell lines tested. In fact, both
MYXV and vvDD were able to produce only a 0.2- to 3.2-fold increase
in viral progeny than what was used to initiate infection. Again, this
result suggests that EOC spheroids possess physical or molecular
changes in cells that significantly impact the replicative life cycle or
amplification for both MYXV and vvDD in these dynamic structures.
Official journal of the American Society of Gene & Cell Therapy
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Figure 4 MYXV and vvDD oncolysis is reactivated after spheroid reattachment. (a) Schematic representation of spheroid infection followed by reattachment
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culture). Scale bar: 1 mm. (d) Quantification of mean dispersion area was performed using ImageJ software (*P < 0.05). MYXV, Myxoma virus.

Activation of MYXV and vvDD oncolysis upon spheroid
reattachment
We use spheroid reattachment as a general method to assess cell
viability within these structures, as well as to model metastasis
formation due to adhesion of spheroids to secondary sites. To this
end, EOC spheroids were infected for 72 hours prior to transfer to
adherent culture for spheroid reattachment (Figure 4a). Spheroid
cells are allowed to reattach and disperse for another 72 hours,
after which the dispersion area of cells from infected spheroids
was quantified (Figure 4b). Despite lacking a significant oncolytic
cell-killing effect in spheroids while in suspension, oncolysis mediated by both MYXV and vvDD was activated upon spheroid reattachment and significantly reduced the ability of cells to disperse
Official journal of the American Society of Gene & Cell Therapy

from spheroids and form a viable monolayer (Figure 4c,d). Reduced
dispersion was apparent within 24 hours after reattachment and
sustained for up to 4 days (Supplementary Figure S2). Due to its dramatic impact on spheroid cell viability, MRBV infection completely
prevented reattachment of HEYA8 and SKOV3 spheroids (Figure 4c
and Supplementary Figure S2). Although our previous results of cell
viability indicated a marginal effect of vvDD infection on OVCAR8
spheroids (Figure 2c), vvDD completely prevented OVCAR8 spheroid reattachment suggesting a significant reduction of cell viability
in these structures. Interestingly, and in marked contrast to vvDD,
MRBV-infected OVCAR8 spheroid cells were still capable of reattaching and dispersing, but to a lesser extent than mock-infected
controls (Figure 4c,d and Supplementary Figure S2).
Molecular Therapy — Oncolytics (2015) 15013
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We next sought to examine the direct oncolytic effect of all three
viruses on established reattached spheroids (Figure 5a). This facilitates our ability to evaluate their potential to target metastases,
as well as determine whether insensitivity to oncolytic virus infection observed in suspension spheroids also existed in reattached
spheroid nodules. We observed virus infection of attached spheroids with treatment of MYXV, vvDD, and MRBV within 24 hours
using green fluorescent protein expression as a marker (Figure 5b);
this resulted in cytopathic effect in the dispersing adherent cells

Molecular Therapy — Oncolytics (2015) 15013

emanating from attached spheroids while leaving the spheroid
cores relatively intact (Figure 5c). These findings further emphasize
the requirement of cells to be adherent to promote MYXV- and
vvDD-induced oncolysis. Similar to reduced cytopathic efficacy
observed in MRBV infection of OVCAR8 spheroids, we observed
reduced green fluorescent protein expression in MRBV-infected
OVCAR8 attached spheroids when compared with MRBV-infected
HEYA8 and SKOV3 attached spheroids, suggesting decreased viral
entry or replicative potential in OVCAR8 spheroids.

Official journal of the American Society of Gene & Cell Therapy
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efficacy in EOC spheroids for MYXV and vvDD (Figure 2b,c), there
was no significant difference for either MYXV or vvDD to enter
adherent or spheroids cells (Figure 6a). In contrast, we observed a
significant reduction in the ability of MRBV to enter spheroids for all
three EOC cell lines when compared with adherent cells.

MRBV entry into EOC spheroid cells is significantly reduced
Since we had observed an appreciable difference for MYXV and
vvDD to induce oncolysis of spheroids, and slower infection kinetics of spheroids by MRBV particularly in OVCAR8 spheroids, we
sought to determine the efficiency of virus entry into adherent cells
and spheroids. To achieve this end, we titrated both the amount of
virus remaining in the supernatant and that which had entered the
cell. Although we had observed a significant reduction in oncolytic

MRBV binding and infection of EOC spheroids requires low-density
lipoprotein receptor (LDLR) expression
To investigate the acquired mechanism determining the enhanced
ability of MRBV to enter adherent EOC cells compared with spheroids, we postulated this was due to changes in the expression of
a cell surface receptor required for MRBV entry. Previous studies
have identified the LDLR as a cell surface receptor that is used by
the closely-related vesicular stomatitis virus (VSV). Since the glycoprotein responsible for binding and entry of host cells by VSV shares
80% amino acid sequence homology with MRBV glycoprotein, we
sought to determine if the mechanism of MRBV entry in EOC cells
was LDLR mediated. Indeed, we observed a consistent decrease
in the expression of LDLR protein expression in day-3 spheroids
when compared with adherent cells among multiple EOC cell lines
(Figure 6b). To test this mechanism further, we performed siRNA
knockdown of LDLR to validate whether LDLR is required by MRBV to
gain entry to host cells. LDLR knockdown in SKOV3 cells (Figure 6c)

Table 2

Summary of overall results for MYXV, vvDD, and
MRBV oncolytic efficacy in ovarian cancer adherent cells and
spheroids
HEYA8

MYXV

SKOV3

OVCAR8

ADH

SPH

ADH

SPH

ADH

SPH

++

−

++

−

++

−

vvDD

++

+

++

−

++

++

MRBV

++++

+++

++++

+++

++++

+

ADH, adherent cells; MYXV, Myxoma virus; SPH, spheroids.
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Figure 6 Efficient MRBV entry into ovarian cancer cells requires low-density lipoprotein receptor (LDLR) expression. (a) HEYA8, SKOV3, and OVCAR8
cells were seeded to adherent and spheroid culture, and infected with MRBV, vvDD, and MYXV for 1 hour at 4 °C to allow adsorption. Virus titers from
cell lysates are shown relative to total virus collected (i.e., supernatant + cells). MRBV titers were determined using supernatant only. Virus treatment in
the absence of cells were used as controls. MRBV binding was significantly reduced in EOC spheroids for all three cell lines tested when compared with
MYXV and vvDD. (b) LDLR protein expression is reduced in ovarian cancer day-3 spheroids as compared with proliferating adherent cells; this results was
also observed in the HEY and OVCAR3 cell lines. (c) Western blot demonstrating siRNA-mediated LDLR knockdown performed by transient transfection
of SKOV3 cells. (d) MRBV binding is reduced in SKOV3 cells with LDLR knockdown as compared with siNT control transfected cells. (e) LDLR knockdown
significantly decreases MRBV-mediated oncolytic SKOV3 cell death as determined by CellTiter-Glo after 24 hours, whereas there is no effect on viability
after MYXV and vvDD infection (*P < 0.05; **P < 0.01). EOC, epithelial ovarian cancer; MYXV, Myxoma virus.
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resulted in a significant decrease in MRBV entry (Figure 6d), and a
resultant increase in cell viability in MRBV-infected cells as compared with knockdown control SKOV3 cells (Figure 6e). In contrast,
knockdown of LDLR had no effect on cell viability due to infection
with MYXV or vvDD.
DISCUSSION
Most ovarian cancer patients are diagnosed with late-stage metastatic
disease, are subjected to multiple successive recurrences, and will
eventually succumb to chemotherapy-resistant disease. Thus, the first
objective of this study was to test the potential of MYXV, vvDD, and
MRBV as therapeutic alternatives to conventional chemotherapeutics
for the treatment of metastatic EOC. A second important objective was
to demonstrate that testing viral oncolytics in a uniquely different culture-based model system, i.e., three-dimensional spheroids, can elicit
unforeseen results and uncover important mechanisms controlling
virus infection and efficacy. MRBV is clearly the most potent oncolytic
virus among the EOC cell lines that we tested in both proliferating
adherent cells and quiescent 3D spheroids. However, we are the first
to discover that endogenous downregulation of LDLR protein expression in spheroids has the potential to reduce MRBV oncolytic efficacy.
Although the larger and slower poxviruses MYXV and vvDD were less
infectious and produced less virus progeny in ovarian cancer cell lines
and spheroids, virus-infected spheroids displayed reduced capacity
to reattach and grow due to reactivation of virus infection. Given our
results, we propose that early in vitro testing of viral oncolytic agents
should consider using an experimentally-tractable cell culture system
such as ours that mimics unique mechanisms of disease metastasis.
We observed significant differential effects of the three viruses
among the three cell lines and when assessing the different steps of
metastasis as modeled in our culture system, particularly when comparing adherent to spheroid cells (summarized in Table 2). In adherent culture, MRBV clearly exhibited the highest oncolytic activity.
Adherent monolayer cultures represent proliferating ovarian cancer
cells with intact growth factor signaling. In contrast, overall efficacy
was reduced among the three viruses in spheroids. In particular, the
almost universal MRBV oncolytic efficacy was dramatically reduced
in OVCAR8 spheroids. We demonstrate that one of the key receptors MRBV utilizes to bind and enter ovarian cancer cells is LDLR;
surprisingly, we also show that the LDLR receptor is downregulated
in spheroids compared with adherent proliferating ovarian cancer
cells. This could be related to the dormant phenotype and the fact
that the overall anabolic metabolism is reduced in spheroids.18,19,23 It
has been reported previously that densely-packed cells downregulate LDLR resulting in decreased cholesterol metabolism in gynecologic cancer cell lines.24,25 It is possible that this same effect of LDLR
downregulation is occurring in densely-packed cells comprising
EOC spheroids thereby reducing initial virus entry. It is important
to note, however, that after this initial delay in virus entry, MRBV is
capable of infecting spheroid cells and producing infectious viral
progeny albeit with slower kinetics compared with adherent proliferating cells. We postulate that the dormant phenotype observed in
cultured spheroids is analogous to microregions of tumors that are
avascular or lack essential growth factor and nutrient availability. To
that end, it would be important to address LDLR expression level in
ovarian tumors directly, and assess whether modifications can be
made to increase MRBV binding and entry to the potentially resistant subpopulations due to altered metabolism.
MRBV is the most potent of the three oncolytic viruses tested. It
exhibited the greatest killing in the three cell lines. It had the fastest kinetics and generated the most infectious progeny. This is
Molecular Therapy — Oncolytics (2015) 15013

most likely supported by the fact that MRBV is a rhabdovirus with
a short life cycle and small genome. This has also been observed
for MRBV in other cancer cell systems, and its related family members, such as the most widely-studied rhabdovirus, VSV.15,26 MRBV
was originally identified from a large biorepository of rhabdoviruses
as having potent activity in several different cancer cell lines.15 This
group also developed the double point mutant MRBV MG1, which
exhibited enhanced growth in cancer cells and reduced effects in
normal cells. MRBV is rapidly entering clinical trials with engineered
vectors expressing tumor-associated antigens, such as MAGE M3.27
We postulate that identifying similar tumor-associated antigens
specific for ovarian cancer, perhaps other MAGE proteins,28 could
be rapidly applied to develop clinically-useful MRBV oncolytic viral
vectors. It has become increasingly evident that oncolytic virus efficacy in vivo relies on eliciting an active immune response, which
may lead to more durable antitumor effects in the long-term.29 We
recognize that the cell culture-based system used in this report is
unable to assess the contribution of the immune system; however,
we argue that our in vitro ovarian cancer spheroid metastasis model
is a useful, rapid and widely-amenable experimental tool for initial
testing of novel oncolytic vectors across histologic and molecularlydefined cancer subtypes, particularly using patient-derived malignant tumor cells.
Generally speaking, ovarian cancer spheroids are more restrictive
to viral oncolysis. One argument could be made regarding the general physical structure of spheroid that may make them less readily infected by viruses. Interestingly, we found that for MYXV and
vvDD viruses there was no difference in binding of these viruses to
adherent monolayer cultured cells compared with 3D spheroids in
suspension. However, the ability of these two different viruses to
complete their lifecycle was dramatically restricted in spheroids. In
this case, this is most likely due to the inherent phenotype of ovarian
cancer cells in spheroids, namely downregulation of AKT signaling,
induction of autophagy, and a cellular quiescent phenotype.18,19,23
Oncolytic viruses typically rely on overactive or mutant growth factor signaling to promote their life cycle and this constitutes a critical
cancer-specific tropism.30 We have shown in other reports that the
AKT signaling pathway is markedly downregulated in ovarian cancer
cell spheroids, and this directly affected MYXV oncolytic efficacy.22
Soares and colleagues have shown that increased levels of phosphorylated AKT are required for late-stage vvDD morphogenesis
and production of virus progeny.31 Likewise, phosphorylated AKT is
also required for permissive infection of MYXV; however, the specific
stage of the requirement is currently undefined.32 In our previous
study, we demonstrated that activated AKT levels are significantly
reduced within spheroids as compared with adherent EOC cells, but
this activity is reinstated upon spheroid reattachment.19 Our present
results are in agreement with this phenomenon, since reattachment of spheroids triggered the reactivation of MYXV and vvDD-
mediated oncolytic killing of dispersing cells.
MYXV and vvDD reach late-stage virus production in spheroids
yet are restricted to cause cell death. This restriction is quickly
relieved upon spheroid reattachment when the dormant-to-proliferative switch” occurs19 and cells are again susceptible to viral-mediated oncolytic cell death. This result is consistent with our previous
study using MYXV in patient-derived spheroids.22 We use spheroid
reattachment as a model of intraperitoneal metastatic seeding of
malignant cells akin to what is observed in patients.16,17,33,34 In fact,
OVCAR8-generated spheroids were dramatically susceptible to
vvDD-induced cell death when using spheroid reattachment as
an assay. It would be interesting to determine what mechanisms
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are utilized by vvDD to affect OVCAR8 spheroid cells compared
with MRBV, an agent that was largely ineffective only in OVCAR8
spheroids. This knowledge may uncover novel strategies to engineer MRBV to make it more widely applicable to ovarian tumors of
different histologies and pathobiologies across the ovarian cancer
patient spectrum. Given our results, we propose that tumor-homing
oncolytic viruses could be potent therapeutic agents with particularly high tropism and efficacy to seek and destroy these persistent
microscopic structures in a patient after surgical debulking of macroscopic disease.
MATERIALS AND METHODS
Cell culture
HEYA8, SKOV3, HEY, Vero, HeLa, and BGMK cell lines were cultured in
Dulbecco’s Modified Eagle medium (Wisent) supplemented with 5%
fetal bovine serum (Wisent). OVCAR8 and OVCAR3 cells were cultured in
Dulbecco’s Modified Eagle medium/F12 (Wisent) containing 10% fetal
bovine serum. All cell lines were cultured in a humidified environment at 37
°C with 5% CO2.
Ascites fluid obtained from ovarian cancer patients at the time of
debulking surgery or paracentesis was used to generate primary cell cultures as described previously.22 Cells were cultured in Dulbecco’s Modified
Eagle medium/F12 supplemented with 10% fetal bovine serum and grown
in a 37 °C humidified atmosphere of 95% air and 5% CO2. Since these represent primary cell cultures, all experiments were performed between passages 3 and 5. All patient-derived cells were used in accordance with institutional human research ethics board approval (UWO HSREB 12668E).

Virus production
MYXV, vvDD, and MRBV were amplified in BGMK, HeLa, and Vero cell lines,
respectively. BGMK cells were infected with MYXV at MOI 10 for 1 hour. After
48 hours of infection, cells were harvested and lysed, cell debris was pelleted
by centrifugation and supernatant with MYXV was purified.35 HeLa cells were
infected with vvDD at MOI 0.1 and 60 hours after infection cells and virus
were harvested and purified similar to MYXV. Vero cells were infected with
MRBV at MOI 0.01. After 20 hours of infection, supernatant was collected
and virus was purified using a 0.2 micron filter. All virus constructs have been
engineered previously to express green fluorescent protein from endogenous viral promoters: MYXV,36,37 vvDD,14 MRBV.26 The MRBV MG1 mutant
strain used in these experiments has been described previously.26

Viral titer quantification
Quantification of MYXV, vvDD, and MRBV titers were performed using BGMK,
HeLa, and Vero cells, respectively. Virus titers were determined through limiting dilutions of virus on BGMK, HeLa, or Vero. Agarose overlays and plaque
assays were performed to determine virus concentration.
Adherent culture. HEYA8, SKOV3, and OVCAR8 cells were seeded at 25,000
cells/well of a 24-well plate and infected with MYXV, vvDD, or MRBV at
MOI 10. After 48 hours MRBV infection, and 4 days after MYXV and vvDD
infection, cells and supernatant were harvested together for virus content.
MYXV, vvDD, and MRBV were titrated on BGMK, HeLa, and Vero cell lines,
respectively.
Spheroid culture. HEYA8, SKOV3, and OVCAR8 cells were seeded at 50,000
cells/well of a 24-well Ultra-Low Attachment cluster plate and allowed to
form spheroids for 3 days. Spheroids were then infected while in suspension with MYXV, vvDD, or MRBV at MOI 10. Seventy-two hours after MRBV
infection, and 5 days after MYXV and vvDD infection, spheroids and supernatant were harvested together for virus content. Spheroids were triturated
using a 26-gauge needle and titered as described above.

Virus infection of EOC cells
HEYA8, SKOV3, and OVCAR8 were seeded at 5,000 cells/well of a 96-well
plate and were infected the following day with MYXV, vvDD, or MRBV at a
MOI 0.001, 0.01, 0.1, 1, and 10. The appropriate UV-inactivated virus at MOI
10 or no virus (mock infected) was used as controls. Seventy-two hours
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postinfection, viability was assayed using CellTiter-Glo Luminescent Cell
Viability Assay (Promega, Madison, WI).
For infection of EOC spheroids, cells were seeded at 50,000 cells/well of
a 24-well Ultra-Low Attachment cluster plate (Corning, Corning, NY) and
spheroids were allowed to form over 72 hours. Spheroids were then infected
at MOI 0.01, 0.1, 1, and 10, using the same controls as described for adherent
cell infections.
For infection of reattached spheroids, spheroids were formed as previously described, in the absence of virus, and transferred to six-well tissue
culture-treated plates for reattachment. Forty-eight hours after reattachment, spheroids were then infected at MOI 10 based on the initial seeding
of 50,000 cells/well of a 24-well Ultra-Low Attachment plate. Spheroids were
imaged 24 hours after infection then fixed and stained at 72 hours postinfection using HEMA3 (Fisher HealthCare, Ottawa, Ontario, Canada). Phase
contrast and fluorescence images of infected cells and spheroids were captured during each experiment using a Leica DMI 4000B inverted microscope.
Fluorescence and phase contrast overlays were generated using Adobe
Photoshop.

Kinetics of infection and cell viability
HEYA8, SKOV3, and OVCAR8 cells were seeded as described above for both
adherent and spheroid cultures. Cells were then infected with an MOI 10 to
allow for maximum virus infection and achieve synchronous virus lifecycle
among all cells within the culture. Viability was then assayed using CellTiterGlo at 12, 24, 36, 48, 72 hours, and 4 and 5 days after infection for adherent
cultures and at 24 hours intervals for up to 6 days with spheroids. To assay
cell viability in spheroids, spheroids were collected and pelleted, followed
by resuspension in CellTiter-Glo and trituration with a 26-gauge needle.
Luminescence was measured using a Wallac Plate Reader (PerkinElmer,
Waltham, MA).

Spheroid reattachment quantification
Cells were seeded at 50,000 cells/well of a 24-well Ultra-Low Attachment
cluster plate to form spheroids over 72 hours. Spheroids were infected with
MYXV, vvDD, or MRBV at MOI 10. Spheroids were reattached by transferring
to six-well tissue culture plates. Spheroids were permitted to attach and disperse for an additional 72 hours prior to fixing and staining using HEMA3.
Dispersion areas were calculated using ImageJ 1.48 software (NIH) by subtracting the area of the core spheroid from the total area of the dispersion
zone.

Virus entry quantification
Adherent cells and spheroids were infected with MOI 10 MYXV, vvDD, and
MRBV for 1 hour at 4 °C to allow virus infection of cells, but to prevent virus
uncoating that would affect subsequent quantification of infectious virus
titers. After 1 hour of virus adsorption, supernatant and cells were separated
and cell pellets were washed twice with PBS. Spheroids and adherent cells
were triturated as described above to ensure that all nonadsorbed virus was
released. Virus content from supernatants and cell pellets were titrated separately to quantify the proportion of virus that had entered adherent cells and
spheroids.

Immunoblotting
Cell lysates were generated using a modified radioimmunoprecipitation
assay (RIPA) buffer (50 mmol/l HEPES pH7.4, 150 mmol/l NaCl, 10% glycerol,
1.5 mmol/l MgCl2, 1 nmol/l ethylene glycol tetraacetic acid, 1 nmol/l sodium
orthovanadate, 10 mmol/l sodium pyrophosphate, 10 mmol/l sodium
fluoride, 1% Triton X 100, 1% sodium deoxycholate, 0.1% sodium dodecyl
sulfate, 1 mmol/l phenylmethylsulfonyl fluoride, 1× protease inhibitor cocktail (Roche, Laval, QC)) as described previously.38 Lysates were incubated
on ice for 20 minutes and vortexed to ensure complete lysis. Lysates from
day-3 spheroids were triturated using a 26-gauge needle to help facilitate
lysis. Protein concentrations were then determined by Bradford assay using
Protein Assay Dye Reagent (BioRad, Mississauga, ON). Thirty micrograms of
each lysate were run on an 8% sodium dodecyl sulphate-polyacrylamide gel
electrophoresis gel and transferred to a polyvinylidene difluoride membrane
(Roche, Mississauga, Ontario, Canada). Blots were blocked with 5% skim milk
in Tris-buffered saline with Tween 20 (TBST; 10 mmol/l Tris-HCl, pH 8.0, 150
mmol/l NaCl, 0.1% Tween 20). After 1 hour of blocking, blots were incubated
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on a rocking platform shaker at 4 °C overnight with specific antibodies at
1:1,000 dilution in bovine serum albumin (BSA)/TBST (anti-LDLR (Abcam,
ab14056; Cambridge, MA); anti-actin (Sigma)). Blots were washed using TBST
and incubated with peroxidase-conjugated anti-rabbit IgG (GE Healthcare)
at 1:10,000 dilution, 5% skim milk/TBST (LDLR) or 5% bovine serum albumin/TBST (actin), for 1 hour at room temperature. Blots were washed again
using TBST followed by incubation with Luminata Forte Western horseradish
peroxidase substrate (Millipore, Etobicoke, Ontario, Canada) and visualization of bands with the ChemiDoc MP System (BioRad, Mississauga, Ontario,
Canada).

LDL receptor knockdown
SKOV3 cells were seeded in 48-well dishes and transfected the next day
with siLDLR SMARTPool RNA or the siNT nontargeting control RNA using
DharmaFECT 1 transfection reagent (Dharmacon). At 48 hours post-transfection, cells were used for infection experiments (virus entry (MRBV at MOI 0.1)
and cell viability (MYXV and vvDD at MOI 1; MRBV at MOI 0.1)) as described
above.

Statistical analysis
Statistical significance was determined by unpaired two-tailed Student’s
t-test or one-way analysis of variance using GraphPad Prism 6 (GraphPad
Software, San Diego, CA). Statistical significance was set at P < 0.05.
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